Opioid tolerance: The clinical perspective

British Journal of Anaesthesia

Volumn 81, Issue 1, 1998, Pages 58-68

  Collett, Beverly Jane ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Analgesics opioid; Cancer; Children; Opioid addiction; Opioid tolerance; Pain, chronic

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; FENTANYL; LEVORPHANOL; METHADONE; MORPHINE; OPIATE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ANALGESIA; CANCER PAIN; CHRONIC PAIN; COLON OBSTRUCTION; CONSTIPATION; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; NAUSEA; NONHUMAN; OPIATE ADDICTION; PATIENT CONTROLLED ANALGESIA; PEDIATRICS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME;

EID: 0031874618     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/81.1.58     Document Type: Article

References (106)

1. Andersen S, Leikersfeldt G. Management of chronic non-malignant pain. British Journal of Clinical Practice 1996; 50: 324-330.
2. Angell M. The quality of mercy. New England Journal of Mediane 1982; 306: 98-99.
3. Anonymous. It's over, Debbie. A piece of my mind. Journal of the American Medical Association 1998; 259: 272.
4. Arner S, Arner B. Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiologica Scandinavica 1985; 29: 32-36.
5. Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and intrathecal opioids - a nationwide survey. Acta Anaesthesiologica Scandinavica 1998; 32: 253-259.
6. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1998; 33: 11-23.
7. Bilsky EJ, Inturrissi CE, Sadee W, Hruby VJ, Porreca F. Competitive and non-competitive antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioids in mice. Pain 1996; 68: 229-237.
8. Brescia FJ, Portenoy RK, Ryan M, Krasnoff L, Gray G. Pain, opioid use, and survival in hospitalised patients with advanced cancer. Journal of Clinical Oncology 1992; 10: 149-155.
9. Bruera E, MacMillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 13-16.
10. Bruera E, MacMillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989; 37: 203-209.
11. Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald N. Methylphenidate associated with narcotics in the treatment of cancer pain. Cancer Treatment Reports 1987; 71: 67-70.
12. Budd K, Drug management of chronic benign pain. International Disability Studies 1987; 9: 30-33.
13. Chapman CR, Harlan FH. Prolonged morphine self-administration and addiction liability. Evaluation of two theories in a bone marrow transplant unit. Cancer 1989; 63: 1636-1644.
14. Chapman CR, Donaldson GW, Jacobson RC, Hautman B. Differences among patients in opioid self-administration during bone marrow transplantation. Pain 1997; 71: 213-223.
15. Clark JK, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. Journal of Pain and Symptom Management 1995; 10: 310-314.
16. Cochin J, Kornetsky C. Development and loss of tolerance to morphine in the rat after single and multiple injections. Journal of Pharmacological Experimental Therapeutics 1964; 145: 1-20.
17. Collin E, Poulain P, Gauvin-Piquard A, Petit G, Pichard-Leandri E. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment? Pain 1993; 55: 319-326.
18. Colpaert FC. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacological Reviews 1996; 48: 355-102.
19. Coyle N. Continuity of care for the cancer patient with chronic pain. Cancer 1989; 63: 2289-2293.
20. Coyle N, Adelhardt J, Foley K, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. Journal of Pain and Symptom Management 1990; 5: 83-93.
21. Coyle N, Breitbart W, Weaver S, Portenoy R. Delirium as a contributing factor to 'crescendo' pain: three case reports. Journal of Pain and Symptom Management 1994; 9: 44-47.
22. Creighton FJ, Ghodse AH. Naloxone applied to conjunctiva as a test for physical opiate dependence. Lancet 1989; i: 748-750.
23. De Leon-Casasola OA, Lema M. Epidural bupivacaine/sufentanil therapy for postoperative pain control inpatients tolerant to opioid and unresponsive to epidural bupivacaine/morphine. Anesthesiology 1994; 80: 303-309.
24. Dubner R. A call for more science, not more rhetoric, regarding opioids and neuropathic pain. Pain 1991; 47: 1-2.
25. Dunbar PJ, Chapman CR, Buckley FP, Gavrin JR. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain 1996; 68: 265-270.
26. Fitzgibbon DR, Galer BS. The efficacy of opioids in cancer pain syndromes. Pain 1994; 58: 429-131.
27. Foley K. The treatment of cancer pain. New England Journal of Medicine 1985; 313: 84-95.
28. Foley K. Controversies in cancer pain: medical perspectives. Cancer 1989; 63: 2257-65.
29. Foley KM. Changing concepts of tolerance to opioids. What the cancer patient has taught us. In: Chapman CR and Foley KM, eds. Current and Emerging Issues in Cancer Pain: Research and Practice. NewYork: Raven Press, 1993; 331-350.
30. France RD, Urban BJ, Keefe FJ. Long term use of narcotic analgesics in chronic pain. Society of Science and Medicine 1984; 19: 1379-1382.
31. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91.
32. Gaylin W, Kass LR, Pellegrino ED, Siegler M. Doctors must not kill. Journal of the American Medical Association 1998; 259: 2139-2140.
33. Glynn CJ, Mather LE. Clinical pharmacokinetics applied to patients with intractable pain: studies with pethidine. Pain 1982; 13: 237-246.
34. Gourlay GK, Plummer JL, Cherry DA, Onley MM, Parish KA, Wood MM, Cousins MJ. Comparison of intermittent bolus with continuous infusion of epidural morphine in the treatment of severe cancer pain. Pain 1991; 47: 135-140.
35. Gourlay GK. Long term use of opioids in chronic pain patients with nonterminal disease states. Pain Reviews 1994; 1: 62-76.
36. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Anaesthesia 1981; 36: 37-39.
37. Hanks GW, Twycross RG. Pain, the physiological antagonist of opioid analgesics. Lancet 1984; i: 1477-1478.
38. Hanks GW, de Conno F, Hanna M, McQuay H, Mercadante S, Meynadier J, Poulain P, Roca i Casas J. Morphine in cancer pain: modes of administration. British Medical Journal 1996; 312: 823-826
39. Hill HF, Chapman CR, Kornell JA, Sullivan KM, Saeger LC, Benedetti. Self-administration of morphine in bone marrow transplant patients reduces drug requirement. Pain 1990; 40: 121-129.
40. Hodes RL. Cancer patients' needs and concerns when using 2. narcotic analgesics. In: Hill CS jr, Fields WS, eds. Advances in Pain Research and Therapy, Vol. 11. New York: Raven Press, 1989; 91-99.
41. Houde RW, Nathan B. Eddy Memorial Lecture: The analgesic connection. In: Harris LS, ed. Problems of Drug Dependence 1984. Proceedings of the 46th Annual Scientific Meeting, The Committee on Problems of Drug Dependence: NIDA Research Monograph 55: 4-13.
42. Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM. Pharmacokinetic-pharrnacodynamic relationships of methadone infusions in patients with cancer pain. Clinical Pharmacology and Therapeuncs 1990; 47: 565-577.
43. Ivarsson M, Neil A. Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross tolerance. Pharmacology and Toxicology 1989; 65: 368-371.
44. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992; 339: 1367-1371.
45. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan 1985; 532-581.
46. Jaffe JH. Misinformation: euphoria and addiction. In: Hill CS jr, Fields WS, eds. Advances in Pain Research and Therapy, Vol 11. New York: Raven Press, 1989; 163-173.
47. Kaasalainen V, Vainio A, Ali-Melkkila T. Developments in the treatment of cancer pain in Finland: the third nation-wide survey. Pain 1997; 70: 175-183.
48. Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW. Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. New England Journal of Medicine 1981; 304: 1501-1505.
49. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Annals of the New York Academy of Sciences 1981; 362: 161-172.
50. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. Journal of the American Medical Association 1973; 223: 665-668.
51. Kupers RC, Konings H, Adraensen H, Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 1991; 47: 5-12.
52. Kupers R, Gybels J. The consumption of fentanyl is increased in rats with nociceptive but not with neuropathic pain. Pain 1995; 60: 137-141.
53. Light AB, Torrance EG. Opium addiction. Archives of Internal Medicine 1929; 44: 1-16.
54. Lyness WH, Smith FL, Heavner JE, Iaconno CU, Garvin RD. Morphine self-administration in the rat during adjuvant arthritis. Life Sciences 1989; 45: 2217-2224.
55. Markley HG. Chronic headache: appropriate use of opiate analgesics. Neurology 1994; 44(suppl 3): S18-S24.
56. Martin WR, Eades CG, Thompson, WO, Thompson JA, Flanary HG. Morphine physical dependence in the dog. Journal of Pharmacology and Experimental Therapeutics 1974; 189: 759-771.
57. Maruta T, Swanson DW, Finlayson RE. Drug abuse and dependency in patients with chronic pain. Mayo Clinic Proceedings 1979; 54: 241-244.
58. McQuay HJ, Bullingham RES, Moore RA. Acute opiate tolerance in man. Life Sciences 1981; 28: 2513-2517
59. McQuay HJ. Opioids in chronic pain. British Journal of Anaesthesia 1989; 63: 213-226.
60. McQuay HJ. Potential problems of using both opioids and local anaesthetic. British Journal of Anaesthesia 1988; 61: 121.
61. McQuay HJ, Jadad AR, Carroll D, Faura C, Glynn CJ, Moore RA, Lau Y. Opioid sensitivity of chronic pain: a patient-controlled analgesia method. Anaesthesia 1992; 47: 757-767.
62. Merry AF, Schug SA, Richards EG, Large RG. Opioids in chronic pain of non-malignant origin: state of the debate in New Zealand. European Journal of Pain 1992; 13: 39-43.
63. Morgan JP, Puder KS. Postoperative analgesia: variations in prescribed and administered opioid dosages. In: Hill CS, Fields WS, eds. Advances in Pain Research and Therapy, Vol. 11. NewYork: Raven Press, 1989; 175-180.
64. Moulin DE, Ling GSF, Pasternak GW. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 1988; 33: 233-239.
65. Moulin DE, Iezzi A, Amireh R, Sharpe W, Boyd D, Mersky H. Randomized trial of oral morphine for chronic non-cancer-pain. Lancet 1996; 347: 143-147.
66. Neil A. Morphine and methadone-tolerant mice differ in cross-tolerance to other opiates. Archives of Pharmacology 1982; 320: 50-53.
67. O'Brien CP. Drug addiction and drug abuse. In Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1995; 557-577.
68. Pappagailo M, Campbell JN. Chronic opioid therapy as alternative treatment for post-herpetic neuralgia. Annals of Neurology 1994; 35: S54-S56.
69. Penn RD, Paice JA. Chronic intrathecal morphine for intractable pain. Journal of Neurosurgery 1987; 67: 182-186.
70. Plummer JL, Cherry DA, Cousins MJ, Gourlay GK, Onley MM, Evans KHA. Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 1991; 44: 215-220.
71. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986; 25: 171-186.
72. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-286.
73. Portenoy RK. Chronic opioid therapy in nonmalignant pain. Journal of Pain and Symptom Management 1990; 5: S46-S62.
74. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. Cancer Surveys 1994; 21: 49-65.
75. Portenoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in Pain Research and Therapy. Seattle: IASP Press, 1994: 247-287.
76. Porter J, Jick H. Addiction rare in patients treated with narcotics. New England Journal of Medicine 1980; 302: 123.
77. Ralphs JA, C de C Williams A, Richardson PH, Pither CE, Nicholas MK. Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff-controlled cocktail methods. Pain 1994; 56: 279-288.
78. Redmond DE, Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. Annual Reviews in Neuroscience 1984; 7: 443-478.
79. Rinaldi RC, Steindler EM, Wilford BB, Goodwin D. Classification and standardization of substance abuse terminology. Journal of the American Medical Association 1988; 259: 555-557.
80. Robins LN, Davis DH, Nurco DN. How permanent was Vietnam drug addiction? American Journal of Public Health 1974; 64 (suppl O): 38-43.
81. Sandgren JE, McPhee Ms, Greenberger NJ. Narcotic bowel syndrome treated with clonidine. Annals of Internal Medicine 1984; 101: 331-334.
82. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. Journal of Pain and Symptom Management 1993; 8: 279-288.
83. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long-term survey of morphine in cancer pain patients. Journal of Pain and Symptom Management 1992; 7: 259-266.
84. Sjogren P, Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989; 39: 5-11.
85. Sjogren P, Jensen N-H, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 313-316.
86. Sosnowski M,Yaksh TL. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990; 73: 1141-1147.
87. Stein C, Yassouridis A. Peripheral morphine analgesia. Pain 1997; 71: 119-121.
88. Stevens CW.Yaksh TL. Studies of morphine and D-ala-D-leuenkphalin (DADLE) cross-tolerance after continuous intrathecal infusion in the rat. Anesthesiology 1992; 76: 596-603.
89. Taub A. Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kitahata LM, Collins JG, eds. Narcotic Analgesics in Anaesthesiology. Baltimore/London: Williams & Wilkins 1982; 199-208.
90. Tennant FS, Uelmen GF. Narcotic maintenance for chronic pain: medical and legal guidelines. Postgraduate Medicine 1983; 73: 81-94.
91. Tennant F, Robinson D, Sagherian A, Seecof R. Chronic Opioid Treatment of Intractable, Non-malignant Pain. NIDA Research Monograph 1998; 81: 174-180.
92. Twycross RG. Clinical experience with diamorphine in advanced malignant disease. International Journal of Clinical Pharmacology 1974; 9: 184-198.
93. Urban BJ, France RD, Steinberger EK, Scott DL, Maltbie AA. Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1986; 24: 191-196.
94. Ventafridda V,Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 851-6.
95. Wall PD. Neuropathic pain. Pain 1990; 43: 267-268.
96. Wallenstein SL, Houde RW, Portenoy R, Lapin J, Rogers A, Foley K. Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain 1990; 41: 5-13.
97. Warncke T, Breivik H, Vainio A. Treatment of cancer pain in Norway. A questionnaire study. Pain 1994; 57: 109-116.
98. Weissman DE, Haddox JD. Opioid pseudoaddiction: an iatrogenic syndrome. Pain 1989; 36: 363-366.
99. Wood MM, Cousins MJ. Iatrogenic neurotoxicity in cancer patients. Pain 1989; 39: 1-3.
100. World Health Organisation, Cancer pain relief. Geneva: WHO, 1986.
101. Vaster M, Maxwell LG. Opioid agonists and antagonists. In: Schechter NL, Berde CB, Vaster M, eds. Pain in Infants, Children and Adolescents. Baltimore: Williams and Wilkins, 1993; 145-171.
102. Yaksh TL. Tolerance: factors involved in changes in the dose-effect relationship with chronic drug exposure. In: Basbaum AI, Besson J-M, eds. Towards a New Pharmacotherapy of Pain. Chichester: John Wiley & Sons, 1991; 157-179.
103. Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organisation guidelines for cancer pain relief. A 10 year prospective study. Pain 1995; 63: 65-76.
104. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. Journal of Pain and Symptom Management 1992; 7: 69-77.
105. Zenz M. Morphine myths: sedation, tolerance and addiction. Postgraduate Medical Journal 1991; 67 (suppl 5): S100-S102.
106. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075-1076.